The rise and fall of beta-agonists in the treatment of ARDS
Critical Care, 04/10/2012Bassford CR et al.
The ALTA trial was terminated on the grounds of futility after it became clear that salbutamol did not affect ventilator–free days. The BALTI–2 trial was terminated for similar reasons alongside concerns about safety and tolerability. Together these findings suggest that the routine administration of β–agonists as a treatment for acute respiratory distress syndrome (ARDS) should be avoided.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.